You are here
Dr. Luis Jodar is Global Vice President and Head for Vaccines Medical Development and Medical/Scientific Affairs at Pfizer Inc. and heads the Pfizer’s vaccines medical and clinical affairs group worldwide and approves clinical development programs for Pfizer vaccine’s portfolio post proof of concept. Dr. Jodar has held different positions at Pfizer including Vice president, Vaccines, MDG/SA; Head of Vaccines, Medical Affairs, Emerging Markets and Executive Director for Clinical and Scientific Affairs for Asia Pac at Wyeth.
Before joining the industry, from 2002-2008, Dr. Jodar was Deputy Director General at the International Vaccine Institute (IVI) in Seoul, Korea, a UN International Organization for the development, introduction and use of new vaccines and was responsible for all pre-licensure and post-licensure clinical trials, epidemiological, outcomes and policy research. Dr. Jodar was also adjunct professor at Seoul National University, School of Public Health and Director of the IVI Vaccinology Course for the Asia Region.
Previously, from 1996-2002, Dr. Jodar worked at the World Health Organization leading the vaccine research and introduction of meningococcal vaccines globally and at the European Commission in Brussels as the focal point of the Task Force for Vaccines and Viral Diseases.
Dr. Jodar is a neuroimmunologist with doctoral and post-doctoral training in Madrid, Osaka and Nagasaki Universities.
Dr. Jodar has worked in vaccine programs in more than 50 countries globally, published in the most accredited peer-reviewed journals (the Lancet, NEJM, Nature Medicine) with a track-record in public private partnerships with more than100MUS$ in grants. He teaches vaccinology courses at the Institut Pasteur in France and at Annecy Advanced Course of Vaccinology.
He has received several honors including the “cross of officer of the order of civil merit” from the King of Spain for his work in vaccines and vaccination in developing countries
Specialties: International health, vaccine R&D, clinical trials and epidemiology, vaccine policy, public and private partnerships, scientific and government affairs, program development, product and business development, competitive analyses, strategic alliances.